TG Therapeutics Inc
TGTX
Market Cap$4.65B
Close$
$-27.53
186.3% downside
Current Fair Value
186.3% downsideOvervalued by 186.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.65 Billion |
|---|---|
| Enterprise Value | $4.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.16 |
| Beta | 1.95 |
| Outstanding Shares | 146,740,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 71.19 |
|---|---|
| PEG | 22.98 |
| Price to Sales | 10.63 |
| Price to Book Ratio | 31.89 |
| Enterprise Value to Revenue | 10.02 |
| Enterprise Value to EBIT | 48.22 |
| Enterprise Value to Net Income | 75 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About TG Therapeutics Inc
CEO: Michael Weiss